Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma

NCT00168740 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00168740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00168740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
April 30, 1995
Completion date
Not reported
Enrollment
150
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade or follicular b-cell non-hodgkin's lymphoma